secwatch.observer — SEC 8-K summary
======================================

Issuer:     BOSTON SCIENTIFIC CORP (BSX)
CIK:        0000885725
Form:       8-K
Filed at:   2025-04-23T23:59:59+00:00
Accession:  0000885725-25-000023
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Boston Scientific Q1 sales $4.66B (+20.9% reported, +18.2% organic), EPS beat guidance
--------------------------------------------------------------------------------

- GAAP EPS $0.45 (up 36% YoY); adjusted EPS $0.75, above guidance $0.66-0.68.
- Cardiovascular segment sales grew 26.2% reported (25.6% organic); MedSurg +11.7% reported (+5.3% organic).
- U.S. sales up 31.1%; EMEA +5.5%, APAC +8.2%, LACA +4.4%.
- FY2025 outlook: organic +12-14%, adj. EPS $2.87-$2.94; Q2: organic +13-15%, adj. EPS $0.71-$0.73.
- Closed Bolt Medical acquisition; agreed to acquire SoniVie Ltd. for TIVUS hypertension denervation technology.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/885725/000088572525000023/0000885725-25-000023-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/885725/000088572525000023/bsx-20250423.htm
  HTML page:      https://secwatch.observer/filing/0000885725-25-000023

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer